CTSO vs. LUCD, NSPR, DRIO, DXR, GBS, XAIR, HSAQ, CTCX, APYX, and CODX
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Lucid Diagnostics (LUCD), InspireMD (NSPR), DarioHealth (DRIO), Daxor (DXR), GBS (GBS), Beyond Air (XAIR), Health Sciences Acquisitions Co. 2 (HSAQ), Carmell (CTCX), Apyx Medical (APYX), and Co-Diagnostics (CODX). These companies are all part of the "surgical & medical instruments" industry.
Lucid Diagnostics (NASDAQ:LUCD) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
Lucid Diagnostics presently has a consensus target price of $2.75, indicating a potential upside of 195.79%. Cytosorbents has a consensus target price of $2.50, indicating a potential upside of 184.09%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Cytosorbents.
Cytosorbents has a net margin of -78.43% compared to Cytosorbents' net margin of -2,169.07%. Lucid Diagnostics' return on equity of -120.24% beat Cytosorbents' return on equity.
Cytosorbents received 410 more outperform votes than Lucid Diagnostics when rated by MarketBeat users. Likewise, 79.67% of users gave Cytosorbents an outperform vote while only 59.52% of users gave Lucid Diagnostics an outperform vote.
74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 4.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Cytosorbents has higher revenue and earnings than Lucid Diagnostics. Cytosorbents is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lucid Diagnostics and Lucid Diagnostics both had 3 articles in the media. Cytosorbents' average media sentiment score of 0.30 beat Lucid Diagnostics' score of 0.22 indicating that Lucid Diagnostics is being referred to more favorably in the media.
Lucid Diagnostics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
Summary
Cytosorbents beats Lucid Diagnostics on 9 of the 17 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
